U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292038) titled 'Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors' on Nov. 17.
Brief Summary: This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Cancers
Intervention:
DRUG: NM6603
NM6603 is an orally administered investigational small-molecule drug evaluated in this dose-escalation study in patients with advanced solid tumors.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: NucMito Pharmaceuticals Co. Ltd.
Disclaimer: Curated by HT Syndication....